We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $288M
1-Year Est. Return 313.93%
This Fund
S&P 500
This Quarter Est. Return
-0.72%
1 Year Est. Return
+313.93%
3 Year Est. Return
+546.33%
5 Year Est. Return
+596.42%
10 Year Est. Return
–
AUM
$404M
AUM Growth
-$53.6M
Cap. Flow
+$15.4M
Cap. Flow %
3.81%
Top 10 Hldgs %
80.03%
Holding
21
New
2
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
PHVS icon
Pharvaris
PHVS
+$11M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$5.29M
3
COGT icon
Cogent Biosciences
COGT
+$2.85M

Top Sells

Rank Stock Value
1
RLYB icon
Rallybio
RLYB
+$2.35M
2
SCPH
scPharmaceuticals
SCPH
+$1.34M

Sector Composition

Rank Sector Weight
1 Healthcare 99.11%
2 Financials 0.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CINC
1
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$81.7M 20.22%
4,337,646
– –
TRDA icon
2
Entrada Therapeutics
TRDA
$273M
$53.7M 13.28%
4,408,379
– –
VOR icon
3
Vor Biopharma
VOR
$1.34B
$31.6M 7.82%
318,086
– –
PEAR
4
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
$28.7M 7.1%
18,631,771
– –
RLYB icon
5
Rallybio
RLYB
$89.3M
$28.2M 6.97%
466,341
-31,250
-6% -$2.35M
IMPL
6
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$26.9M 6.65%
2,884,791
– –
AKUS
7
DELISTED
Akouos Inc
AKUS
$19.4M 4.8%
4,135,784
– –
IDYA icon
8
IDEAYA Biosciences
IDYA
$3.87B
$19.3M 4.77%
1,398,066
– –
SCPH
9
DELISTED
scPharmaceuticals
SCPH
$17.2M 4.25%
3,561,474
-270,000
-7% -$1.34M
ARVN icon
10
Arvinas
ARVN
$600M
$16.8M 4.17%
400,000
– –
CRNX icon
11
Crinetics Pharmaceuticals
CRNX
$9B
$16.1M 3.98%
862,286
– –
PHVS icon
12
Pharvaris
PHVS
$2.48B
$13M 3.21%
+587,600
New +$11M
COGT icon
13
Cogent Biosciences
COGT
$6.02B
$10.2M 2.52%
1,129,200
+417,788
+59% +$2.85M
ISEE
14
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.89M 2.45%
1,027,874
– –
QTTB icon
15
Q32 Bio
QTTB
$447M
$8.94M 2.21%
251,996
– –
RNAM
16
DELISTED
Avidity Biosciences
RNAM
$5.67M 1.4%
390,555
– –
JANX icon
17
Janux Therapeutics
JANX
$1.1B
$5.45M 1.35%
446,266
– –
RXDX
18
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$5.15M 1.27%
+182,370
New +$5.29M
FVAM
19
DELISTED
5:01 Acquisition Corp
FVAM
$3.62M 0.89%
365,126
– –
CABA icon
20
Cabaletta Bio
CABA
$529M
$2.19M 0.54%
2,064,263
– –
CDTX
21
DELISTED
Cidara Therapeutics
CDTX
$554K 0.14%
56,726
– –

Similar funds

TA
TKG Advisors Valparaiso, Indiana $288M AUM 43.58% 1-Year Est. Return
APW
Alliance Private Wealth North Reading, Massachusetts $288M AUM
RCS
Retirement Capital Strategies San Jose, California $288M AUM 17.43% 1-Year Est. Return
FH
FWG Holdings Winter Park, Florida $288M AUM 33.26% 1-Year Est. Return
IAMOG
Investors Asset Management of Georgia Atlanta, Georgia $288M AUM 47.58% 1-Year Est. Return
MP
Maestria Partners Atlanta, Georgia $288M AUM 13.77% 1-Year Est. Return
OL
Owen LaRue Elizabethtown, Kentucky $288M AUM 29.4% 1-Year Est. Return
CFG
Cambridge Financial Group Columbus, Ohio $287M AUM 33.96% 1-Year Est. Return

5AM Venture Management's Q2 2022 Portfolio in Review

As of Q2 2022, 5AM Venture Management held 21 positions worth $404M, down 12% from $458M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

5AM Venture Management deployed $15.4M of net new capital in Q2 2022, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Pharvaris: 587,600 shares worth $13M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Rallybio, an estimated $2.35M trimmed.

  • 5AM Venture Management's largest Q2 2022 buy was Pharvaris: 587,600 shares worth $13M.
  • 5AM Venture Management added most to Cogent Biosciences in Q2 2022, an estimated $2.85M increase.
  • 5AM Venture Management's biggest Q2 2022 reduction was Rallybio, cutting an estimated $2.35M.
  • 5AM Venture Management's ten largest holdings make up 80% of its $404M portfolio in Q2 2022.
  • 5AM Venture Management opened 2 new positions and closed 0 in Q2 2022.
  • 5AM Venture Management's portfolio value fell 12% quarter-over-quarter to $404M.

Based on 5AM Venture Management's 13F filing for Q2 2022, filed 15 Aug 2022.